Drug profile · INN
ranitidine
APO-RANITIDINE
ranitidine (APO-RANITIDINE) is a histamine h2 receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — ranitidine
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 3
- Data quality
- 0.84
Quick answer
ranitidine (APO-RANITIDINE) is a histamine h2 receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H2 receptor antagonist
Primary target: Histamine H2 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ranitidine?
ranitidine (APO-RANITIDINE) is a histamine h2 receptor antagonist. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ranitidine?
APO-RANITIDINE is a marketed brand name for ranitidine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ranitidine?
ranitidine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.